Niraparib
Back to searchMolecule Structure
Scientific Name
Niraparib
Description of the Drug
Niraparib is a poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11793
http://www.drugbank.ca/drugs/DB11793
Brand Name(s)
Zejula
Company Owner(s)
Glaxosmithkline Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Poly [ADP-ribose] polymerase 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL5366 |
| Poly [ADP-ribose] polymerase-1 | SINGLE PROTEIN | INHIBITOR | CHEMBL3105 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1421875 | |
| PharmGKB | PA166131610 | |
| DrugBank | DB11793 | |
| PubChem: Thomson Pharma | 56256045 | |
| PubChem | 24958200 | |
| Nikkaji | J2.851.487E | |
| PDBe | 3JD | |
| BindingDB | 50316226 | |
| EPA CompTox Dashboard | DTXSID50146129 | |
| DrugCentral | 5222 | |
| ChemicalBook | CB42553458 | CB82514860 |
| Guide to Pharmacology | 8275 | |
| rxnorm | ZEJULA | NIRAPARIB |
| ChEBI | 176844 | |
| ZINC | ZINC000043206370 |
